p><location value="LU/us.ca.sandgo" idsrc="xmltag.org">SAN DIEGO</location>--(BUSINESS WIRE)-- <org …
Somaxon Pharmaceuticals Inc. (SOMX) soared last week after the FDA approved its Silenor ... Before the FDA approval, this was a $4.00 stock. It ran to $10.60 before closing at $8.25 last week as major profit taking came into play. Last …
Translation: The upward trend remains intact but there's some disquieting underlying technical deterioration that we must take note ... the economy up to full and steady growth. As for why the stock market is rallying on this lukewarm …
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused ... and the impact of any such financing activity on the level of Somaxon's stock price; the impact of any inability to raise sufficient capital to fund …
Savvy Stock Picks: Wall St. Cheat Sheet’s newest Feature Trades ... 6) Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX): Shares of Somaxon Pharmaceuticals, Inc. closed lower 1.3% to $2.27 per share today. 2.86 million …
Somaxon Pharmaceuticals (SOMX-NASDAQ) has announced essentially failed results from the company’s Phase 2/3 clinical trial evaluating 20 mg and 40 mg of oral nalmefene hydrochloride, an opiate antagonist, in patients with a …
IIROC can make a decision to impose a temporary suspension of trading in a security of a publicly listed company, usually in anticipation of a material news announcement by the company. Trading halts are issued based on the principle that …
Pernix has been active on the acquisition front with the acquisition of Great Southern Laboratories in July 2012 and the merger agreement to acquire Somaxon Pharmaceuticals, Inc. ( SOMX) for $25 million in December 2012. We currently …
Vivendi VIVHY downgraded to underperform from neutral at Exane BNP Paribas. Quicksilver KWK downgraded to Neutral from Buy at UBS on reduced natural gas forecasts and funding concerns. Price target lowered to $11 from $13. Darden …
In the pipeline Somaxon Pharmaceuticals is waiting on an FDA decision on its experimental anti-insomnia drug Silenor. Somaxon (SOMX) chief financial officer Meg McGilley said it's not addictive, which could give it a competitive edge. A …